Barbara Rhoden

Background

About Barbara Rhoden

I am a PhD scientist turned healthcare leader. Whether I’m serving on a board, speaking on a stage, or advising a leadership team, my focus is the same: governing the transition from technical innovation to market reality and sustained adoption.Across nearly two decades at GE Healthcare, Siemens Healthineers, and venture-backed startups, I have governed the launch of 20+ FDA-cleared technologies and provided oversight for portfolios approaching $1B bringing scientific rigor, quality discipline, and commercial judgment to high-stakes enterprise decisions.My operating system is simple: Science · Strategy · Soul:Science: Technical truth, regulatory integrity, and quality governance.Strategy: Positioning, adoption design, and capital deployment oversight.Soul: Brand as a trust covenant and a governed asset that protects enterprise value.Today, my work shows up in three primary capacities:1. Governance & Board ServiceI provide rigorous oversight to de-risk innovation and ensure long-term value, integrating scientific/technical governance, commercial adoption strategy, and the stewardship of stakeholder trust.2. Keynote SpeakingI deliver keynotes and workshops on the human and technical systems that drive clinical adoption. Core themes include:• The Science of Strategic Storytelling: Moving stakeholders from “evidence” to “action”• The Adoption Gap: Solving the “last mile” of healthcare innovation• Trust as a Growth Lever: Governing the stakeholder covenant in high-stakes markets3. Strategic AdvisoryI advise PE-backed and growth-stage platforms on complex commercial challenges where technical innovation, market positioning, and scalable execution are misaligned.Selected Governance & Impact Outcomes:• Directed a GE Healthcare division turnaround that doubled market share and earned the GE Chairman’s Award for best product launch globally.• Oversaw enterprise-scale transformation of sales and service operations across 13 countries at GE Healthcare.• Evaluated strategic partnerships and provided portfolio and divestiture recommendations based on clinical and market evidence.• Provided quality/technical oversight across portfolios with units, including CAPA governance and regulatory audit representation.I am prepared to serve on Strategy & Innovation, Quality, and Technology/Transformation committees, especially for platforms in women’s health, diagnostics, imaging, and digital health.